Taysha Gene Therapies Inc Forecast, price target & analysts
Taysha Gene Therapies Inc Target price 2026 - Analyst rating & recommendation
Taysha Gene Therapies Inc Classifications & Recommendation
Taysha Gene Therapies Inc Price Target
| Target Price | $12.75 |
| Price | $4.63 |
| Potential |
175.38%
register free of charge
|
| Number of Estimates | 14 |
|
14 Analysts have issued a price target Taysha Gene Therapies Inc 2027 .
The average Taysha Gene Therapies Inc target price is $12.75.
This is
175.38%
register free of charge
$19.95
330.89%
register free of charge
$10.10
118.14%
register free of charge
|
|
| A rating was issued by 18 analysts: 17 Analysts recommend Taysha Gene Therapies Inc to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Taysha Gene Therapies Inc stock has an average upside potential 2027 of
175.38%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 9.77 | 1.79 |
| 17.29% | 81.73% | |
| EBITDA Margin | -1,119.24% | -11,190.19% |
| 9.20% | 899.80% | |
| Net Margin | -1,115.66% | -9,354.33% |
| 4.07% | 738.46% |
14 Analysts have issued a sales forecast Taysha Gene Therapies Inc 2026 . The average Taysha Gene Therapies Inc sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an Taysha Gene Therapies Inc EBITDA forecast 2026. The average Taysha Gene Therapies Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
15 Taysha Gene Therapies Inc Analysts have issued a net profit forecast 2026. The average Taysha Gene Therapies Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.34 | -0.51 |
| 5.56% | 50.00% | |
| P/E | negative | |
| EV/Sales | 617.72 |
15 Analysts have issued a Taysha Gene Therapies Inc forecast for earnings per share. The average Taysha Gene Therapies Inc EPS is
This results in the following potential growth metrics and future valuations:
Taysha Gene Therapies Inc...
Current Taysha Gene Therapies Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Wolfe Research |
Locked
➜
Locked
|
Locked | Sep 17 2026 |
| Goldman Sachs |
Locked
➜
Locked
|
Locked | Jul 21 2026 |
| Citizens |
Locked
➜
Locked
|
Locked | Jul 02 2026 |
| Baird |
Locked
➜
Locked
|
Locked | Jun 30 2026 |
| Needham |
Locked
➜
Locked
|
Locked | Jun 30 2026 |
| Citizens |
Locked
➜
Locked
|
Locked | Jun 23 2026 |
| B of A Securities |
Locked
➜
Locked
|
Locked | Jun 23 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
Wolfe Research:
Locked
➜
Locked
|
Sep 17 2026 |
|
Locked
Goldman Sachs:
Locked
➜
Locked
|
Jul 21 2026 |
|
Locked
Citizens:
Locked
➜
Locked
|
Jul 02 2026 |
|
Locked
Baird:
Locked
➜
Locked
|
Jun 30 2026 |
|
Locked
Needham:
Locked
➜
Locked
|
Jun 30 2026 |
|
Locked
Citizens:
Locked
➜
Locked
|
Jun 23 2026 |
|
Locked
B of A Securities:
Locked
➜
Locked
|
Jun 23 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
